Impact of Sodium Zirconium Cyclosilicate Therapy Cessation in Patients with Systolic Heart Failure

Background: Sodium zirconium cyclosilicate (SZC), a newly introduced potassium binder, is indicated for treating hyperkalemia. SZC-incorporated up-titration of renin-angiotensin system inhibitors and mineralocorticoid receptor antagonists has been recommended for those with systolic heart failure, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Imamura, Teruhiko, Narang, Nikhil, Kinugawa, Koichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504621/
https://www.ncbi.nlm.nih.gov/pubmed/36142977
http://dx.doi.org/10.3390/jcm11185330

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504621/
https://www.ncbi.nlm.nih.gov/pubmed/36142977
http://dx.doi.org/10.3390/jcm11185330

Ejemplares similares